References
- Wang Y, Ji P, Liu J, Broaddus RR, Xue F, Zhang W. Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy. Mol Cancer 2009;8:1–13.
- MacDonald V. Chemotherapy: Managing side effects and safe handling. Can Vet j 2009;50:665–668.
- Sirisoma N, Pervin A, Zhang H, Jiang S, Willardsen JA, Anderson MB et al. Discovery of N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine, a potent apoptosis inducer and efficacious anticancer agent with high blood brain barrier penetration. J Med Chem 2009;52:2341–2351.
- Li J, Meng Y, Liu Y, Feng ZQ, Chen XG. F84, a quinazoline derivative, exhibits high potent antitumor activity against human gynecologic malignancies. Invest New Drugs 2010;28:132–138.
- Bavetsias V, Marriott JH, Melin C, Kimbell R, Matusiak ZS, Boyle FT et al. Design and synthesis of Cyclopenta[g]quinazoline-based antifolates as inhibitors of thymidylate synthase and potential antitumor agents(,). J Med Chem 2000;43:1910–1926.
- Gangjee A, Vidwans AP, Vasudevan A, Queener SF, Kisliuk RL, Cody V et al. Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents. J Med Chem 1998;41:3426–3434.
- Conconi MT, Marzaro G, Guiotto A, Urbani L, Zanusso I, Tonus F et al. New Vandetanib analogs: Fused tricyclic quinazolines with antiangiogenic potential. Invest New Drugs 2010;.
- Yang SH, Khadka DB, Cho SH, Ju HK, Lee KY, Han HJ et al. Virtual screening and synthesis of quinazolines as novel JAK2 inhibitors. Bioorg Med Chem 2011;19:968–977.
- Gwanmesia PM, Romanski A, Schwarz K, Bacic B, Ruthardt M, Ottmann OG. The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines. bmc Cancer 2009;9:53.
- Schenone S, Bruno O, Radi M, Botta M. New insights into small-molecule inhibitors of Bcr-Abl. Med Res Rev 2011;31:1–41.
- Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007;109:3207–3213.
- Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009;8:33–40.
- Tobe M, Isobe Y, Tomizawa H, Nagasaki T, Takahashi H, Fukazawa T et al. Discovery of quinazolines as a novel structural class of potent inhibitors of NF-kappa B activation. Bioorg Med Chem 2003;11:383–391.
- Rinderspacher A, Cremona ML, Liu Y, Deng SX, Xie Y, Gong G et al. Potent inhibitors of Huntingtin protein aggregation in a cell-based assay. Bioorg Med Chem Lett 2009;19:1715–1717.
- Alafeefy AM, Kadi AA, Al-Deeb OA, El-Tahir KE, Al-Jaber NA. Synthesis, analgesic and anti-inflammatory evaluation of some novel quinazoline derivatives. Eur J Med Chem 2010;45:4947–4952.
- Burbuliene MM, Mazeikaite R, Vainilavicius P. Regioselective synthesis of N(3)- and O-acylmethyl derivatives of 2-methylthio-4(3H)-quinazolinone. J Heterocyclic Chem 2008;45:607–610
- Bogentoft C, Kronberg L, Danielsson B. Studies on the medicinal chemistry of oxoquinazolines. IV. N- and O-alkylation of some 2-substituted 3,4-dihydro-4-oxoquinazolines. Acta Pharm Suec 1969;6:489–500.
- Hori M, Ohtaka H. Effects of a 2-Substituent on the Ratio of N- and O-Alkylation of 4(3H)-Quinazolinones. Chem Pharm Bull 1993;41:1114–1117.
- Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107–1112.